Table 4.
Univariate analysis for progression-free survival in EGFR-TKI-treated patients
| Characteristics | Number | HR | 95% CI | P-value |
|---|---|---|---|---|
| Age, years | ||||
| ≤61.8 vs >61.8 | 41 vs 34 | 1.344 | 0.847–2.130 | 0.209 |
| Sex | ||||
| Male vs female | 27 vs 48 | 0.566 | 0.344–0.932 | 0.025 |
| Smoking history | ||||
| Yes vs no | 12 vs 63 | 0.689 | 0.366–1.296 | 0.248 |
| Performance status | ||||
| 0–1 vs 2 | 48 vs 27 | 1.544 | 0.940–2.538 | 0.087 |
| Staging | ||||
| IIIB vs IV | 20 vs 55 | 0.799 | 0.472–1.353 | 0.404 |
| HDL-C (mmol/L) | ||||
| ≤0.945 vs >0.945 | 28 vs 47 | 0.151 | 0.086–0.266 | <0.001 |
| EGFR-TKI | ||||
| Gefitinib | 56 | |||
| Erlotinib | 12 | 1.124 | 0.596–2.118 | 0.718 |
| Icotinib | 7 | 1.777 | 0.798–3.959 | 0.159 |
| Mutation type | ||||
| Exon 19 | 33 | |||
| Exon 21 | 37 | 0.614 | 0.380–0.992 | 0.046 |
| Exon 19 + 21 | 5 | 0.928 | 0.360–2.392 | 0.928 |
| HDL-C kinetics | ||||
| Nondecreased | 29 | 0.003 | 0.001–0.018 | <0.001 |
| Normalized | 19 | 0.012 | 0.002–0.062 | <0.001 |
| Decreased | 16 | 0.026 | 0.005–0.130 | <0.001 |
| Nonnormalized | 11 |
Abbreviations: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; HR, hazard ratio; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol.